Valuation : Photocure ASA

Market Cap 1.44B 155M 133M 125M 115M 214M 14.62B 215M 1.48B 575M 7.5B 582M 569M 24.17B P/E 2026 *
18.9x
P/E 2027 * 68.6x
Enterprise Value 1.27B 137M 118M 111M 101M 189M 12.91B 190M 1.31B 507M 6.62B 513M 502M 21.33B EV / Sales 2026 *
1.93x
EV / Sales 2027 * 1.93x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day-2.75%
3 months-3.38%
6 months-14.14%
Current year-14.14%
Current year 6.01
Extreme 6.01
7.39
1 year 5.58
Extreme 5.58
7.39
3 years 4.32
Extreme 4.32
7.39
5 years 4.21
Extreme 4.21
12.8
10 years 3
Extreme 3
17.57
Manager TitleAgeSince
Chief Executive Officer - 2018-10-31
Chief Tech/Sci/R&D Officer - 2021-07-31
Human Resources Officer - 2021-01-31
Director TitleAgeSince
Director/Board Member - 2021-12-31
Chairman - 2023-09-26
Director/Board Member - 2024-05-22
Change 5-day change 1-year change 3-year change Capi.($)
-2.75%-.--% - - 155M
-0.88%-2.15%+58.05%+105.26% 1,024B
-1.15%+2.68%+54.25%+74.19% 663B
-1.44%+0.38%+20.65%+76.13% 453B
+0.14%-0.47%+30.20%+41.44% 352B
-1.33%+4.72%+24.62%+48.58% 304B
-1.15%+0.30%-0.69%+13.20% 252B
-1.55%+1.11%+54.15%+75.59% 236B
-0.88%+1.15%-14.60%-54.96% 206B
-0.15%+3.65%+31.24%+103.39% 187B
Average -1.11%+1.26%+28.65%+53.65% 408.71B
Weighted average by Cap. -0.96%+0.62%+37.63%+68.01%

Financials

2026 *2027 *
Net sales 658M 70.8M 60.92M 57.32M 52.36M 97.95M 6.68B 98.22M 677M 263M 3.43B 266M 260M 11.05B 666M 71.66M 61.66M 58.02M 53M 99.14M 6.77B 99.41M 686M 266M 3.47B 269M 263M 11.18B
Net income 76.33M 8.21M 7.06M 6.65M 6.07M 11.36M 775M 11.39M 78.54M 30.48M 398M 30.83M 30.15M 1.28B 21M 2.26M 1.94M 1.83M 1.67M 3.12M 213M 3.13M 21.61M 8.38M 109M 8.48M 8.3M 352M
Net Debt -169M -18.17M -15.64M -14.71M -13.44M -25.15M -1.72B -25.21M -174M -67.47M -880M -68.25M -66.76M -2.84B -157M -16.88M -14.53M -13.67M -12.49M -23.36M -1.59B -23.42M -162M -62.68M -818M -63.4M -62.02M -2.63B
Logo Photocure ASA
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Employees
100
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
53.50NOK
Average target price
79.67NOK
Spread / Average Target
+48.91%

Quarterly revenue - Rate of surprise